Upside | ||||||
|---|---|---|---|---|---|---|
| AKRO | 1.89% | aa.aa | 46.36 | -5.33% | 3,878 | |
| SLNO | 1.79% | aa.aa | 76.8900 | +4.06% | 2,430 | |
| SMMT | 1.62% | aa.aa | 25.850 | +0.31% | 6,301 | |
| XERS | 1.61% | aa.aa | 4.830 | -1.02% | 33,092 | |
| LQDA | 1.59% | aa.aa | 15.350 | -1.35% | 10,225 | |
| ANAB | 1.55% | aa.aa | 20.44 | -1.45% | 7,491 | |
| MLYS | 1.50% | aa.aa | 15.96 | -2.21% | 9,249 | |
| CVAC | 1.46% | aa.aa | 4.090 | -1.68% | 35,158 | |
| TSHA | 1.42% | aa.aa | 2.750 | -3.51% | 50,003 | |
| ETNB | 1.38% | aa.aa | 9.49 | -1.66% | 14,332 |
ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF is an exchange traded fund launched and managed by Virtus ETF Advisers LLC. The fund invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the LifeSci Biotechnology Clinical Trials Index, by using full replication technique. ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF was formed on December 16, 2014 and is domiciled in the United States.